



iCo Therapeutics Inc
TSX-V: 'iCo'

760-777 Hornby St. Tel: 604-602-9414
Vancouver, BC Fax: 604-602-9699
V6Z 1S4 Canada www.icotherapeutics.com

iCo Therapeutics Inc. is a reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications.

CORPORATE SNAPSHOT

29.8 M Shares Outstanding – Basic
34.4 M Shares Outstanding – Fully diluted
Invested Capital to Date: ~\$13.5 M
Largest Shareholders: Isis Pharmaceuticals ~14%
Management ~16%

Canadian Comparables:

Tekmira Pharmaceuticals "TKM"
YM Biosciences "YM"

CLINICAL STAGE ASSETS

Worldwide exclusive rights

iCo-007: Diabetes-related blindness

- Licensed from: Isis Pharmaceuticals
- 2nd generation antisense target: c-Raf
- Phase I in DME patients: positive interim safety & compelling early efficacy trends
- Other indications: age-related macular degeneration, diabetic retinopathy

iCo-008: Severe ocular allergy

- Licensed from: AstraZeneca/CAT
- Human monoclonal antibody
- Phase II clinical history
- Other indications: severe asthma, inflammatory bowel disease

iCo-009: Fungal and parasitic infections

- Licensed from: UBC
- Potential to be 1st oral Amphotericin B
- Positive pre-clinical data

Oral drug delivery technology

- Non-dilutive funding collaboration completed with CPDD
- Retained all rights to iCo-009

INVESTMENT HIGHLIGHTS

Reprofiling model (e.g. Aspreva, Celegene)
↓ Risk ↓ Cost ↓ Time

Billion dollar markets

Diabetes-Related Blindness	~\$3B+
Fungal & Parasitic Infections	~\$1B+
Severe Ocular Allergies	~\$100M+

Board of Directors industry experience:

- Co-founder of Aspreva (N. Hall)
- Director General of the Association of the British Pharmaceutical Industry (R. Barker)
- Co-founder, Cartesian Capital (B. Jarosz)

Management experience:

- Biotechnology analyst & entrepreneur - Medarex acquisition (A. Rae)
- QLT: BD & Clinical (Drs. J. Clement & P. Hnik)
- Emory University, UCL, Harvard (Dr. S. Ono)
- CFO & I-banker in life sciences (J. Meekison)

2009 STOCK OUTLOOK

Diabetes-related blindness "iCo- 007"

- Early trial results presented
- Final data – safety & efficacy
- Partnering potential

Anti-fungal & Anti-parasitic "iCo- 009"

- Continued preclinical work